



In The United States Patent and Trademark Office

Applicant Clemons et al
Serial No 09/435,257
Filed November 5, 1999
For FK506-Based Regulation of Biological Events

Group Art Unit: 1632

Examiner: Peter Paras, Jr.

ATTN: INT. ARIAD PHARM.

RECEIVED

DEC 13 2002

TECH CENTER 1600/2900

Assistant Commissioner of Patents
Washington, DC 20231

December 3, 2002

Petition for Extension of Time & Supplemental Response

Sir

This paper is in response to the October 7, 2002 Office Communication, a response to which was originally due on November 7, 2002. Applicants request a one month extension for responding and authorize the Commissioner to charge the fee due for such extension to Deposit Account No. 01-2315. The new deadline is now December 7, 2002. Accordingly, this response should be considered timely filed.

Remarks

The Communication noted that our prior Response did not indicate the location in the specification for the genbank accession numbers which are recited in Claims 2 and 3 and further noted that the claims as written rely upon a somewhat awkward reference to cDNA sequences in connection with peptide sequence numbering.

Applicants apologize for those oversights.


The genbank accession numbers recited in the claims are identified in the specification in the table on page 28 in connection with human Calineurin A and B genes.

The reference in claims 2 and 3 to cDNA sequences is corrected in the attached clean and marked up amended claims. The amendments are formalistic changes and introduce no new matter.

Concluding Remarks

In view of the foregoing, applicants request reconsideration and allowance of their claims. If there are any remaining issues that might be resolvable by phone, applicants' attorney encourages the Examiner to call him at the number provided below.

Respectfully submitted,


David L. Bernstein, Reg No. 31,235
ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge, MA 02139
Telephone 617-494-0400 Ext 266

Date Tuesday, December 3, 2002

I hereby certify that this paper is being deposited with the US Postal Service via First Class Mail under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner of Patents, Washington, DC 20231.

Signed


Sue Wilson